4/A: Cadrenal Therapeutics CEO Corrects Stock Option Details in Amended SEC Filing

Quang X. Pham, CEO of Cadrenal Therapeutics, files an amendment to a previous Form 4 to correct the exercise price and expiration date of stock options granted.

Summary

• Quang X. Pham, CEO and Chairman of Cadrenal Therapeutics, Inc. (CVKD), filed an amended Form 4 with the SEC.
• The amendment corrects the exercise price and expiration date of stock options previously reported on January 24, 2025.
• The stock options, granted on January 23, 2025, involve 65,000 shares of common stock.
• The exercise price is $19.79 per share, equal to 100% of the fair market value on the grant date.
• The options vest according to the previously reported schedule and expire on January 22, 2035, ten years from the issuance date.

Sentiment

Score: 7

Explanation: The document is a routine correction of a previous filing, indicating standard corporate governance procedures. The sentiment is neutral to slightly positive as it reflects transparency.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, ensuring transparency and compliance with SEC regulations.

Stakeholder Impact

• Shareholders are informed about the accurate terms of executive stock options.
• The correction ensures transparency and accurate information regarding executive compensation.

Key Dates

Keywords

Form 4, Amendment, Stock Options, Cadrenal Therapeutics, CVKD, Pham Quang X, CEO, SEC Filing, Beneficial Ownership